Savara opened at $4.99, in line with its previous close of $4.99. In the last trading session, the stock traded between $4.67 and $5.03. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Savara is now worth
$ 406.47
Giving a profit of
$ 306.47 (306.47%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 4 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.28 (-5.51%)
Day High
$5.03
Day Low
$4.67
Day Open
$4.99
Prev Close
$4.99
Volume
37,11,164
1W Return
1.25%
1M Return
-2.60%
3M Return
-15.26%
6M Return
-7.91%
1Y Return
8.89%
Fundamentals
Market Cap ($ Mn)
1,040
PE Ratio
-
PB Ratio
7.52
PEG Ratio
-
ROE
-80.59%
ROCE
-69.65%
EPS (TTM)
$-0.21
Investment Returns
1 Week
1.25%
1 Month
-2.60%
3 Months
-15.26%
6 Months
-7.91%
9 Months
-11.87%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Jun 26
0.0
Sep 26
Updates
12Nov
HC Wainwright initiates Savara at Buy, sets $10 price target
HC Wainwright & Co. initiated coverage on Savara Inc. with a Buy rating. Analyst Matthew Caufield set a price target of $10 per share. The initiation signals a positive investment stance for the biotech firm.
Today
21Oct
Savara presents IMPALA post-hoc data at CHEST 2026 for mild aPAP cases
Savara presented IMPALA post-hoc analysis at CHEST 2026 Annual Meeting. Molgramostim reduced A-aDO₂ by 12.7 mmHg vs 0.3 mmHg in placebo. Study focused on aPAP patients with baseline DLco% greater than 70%. SGRQ Activity score improved by 11.1 points in treatment group.
22 days ago
25Aug
Savara presents Phase 3 molgramostim data at ERS Congress 2026
Savara presents three Phase 3 IMPALA-2 trial updates at ERS Congress 2026. Data covers long-term efficacy, safety, and biomarker reductions over 48 weeks. Oral presentation led by Dr. Bruce Trapnell on Sept 6, 2026. Company hosts symposium with key opinion leaders on aPAP management.
2mo ago
21Aug
Savara Inc. grants 139,000 equity awards to eight new hires
Savara Inc. granted equity inducement awards to eight new employees. Awards include 74,500 stock options at $5.37 exercise price. Additional 64,500 RSUs vest fully after two years. Grants approved under NASDAQ Rule 5635(c)(4).
2mo ago
12Aug
Savara Q2 loss widens to $40M on surging commercial costs
Savara Inc. widened its Q2 2026 net loss to $40.2 million, driven by a 78% increase in G&A expenses for commercial preparation. The company maintains ~$173 million in cash and awaits key regulatory decisions for MOLBREEVI in late 2026 and early 2027.
3mo ago
12Aug
Savara secures MOLBREEVI patents in Europe and Australia until March 2041
Savara Pharmaceuticals has obtained patent protection for MOLBREEVI in Europe and Australia until March 2041. Regulatory reviews are ongoing, with the UK’s MHRA expected to decide in Q4 2026 and the EMA in Q1 2027. The US FDA PDUFA date is set for November 22, 2026. Clinical data supports long-term lung function benefits.
